{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-101126","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.795637+00:00","generated_at":"2026-05-15T14:50:44.082262+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Verrica Q4 2025: YCANTH net revenue up 130% to $15.3M; total revenue $35.6M","bullets":["Q4 product revenue $3.7M vs $0.3M YoY; total revenue $35.6M in 2025, up from $7.6M in 2024.","YCANTH dispensed units up 99% to 51,296 in 2025; SG&A cut by over 40% to $35.2M.","Net loss $17.9M ($1.68/share) for full year 2025 vs $76.6M ($14.78/share) in 2024.","Company has no outstanding debt; cash runway extended into Q1 2027.","Phase 3 for common warts initiated; VP-315 advancing to Phase 3 for basal cell carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-101126","json":"https://secwatch.observer/filing/0001193125-26-101126.json","markdown":"https://secwatch.observer/filing/0001193125-26-101126.md","text":"https://secwatch.observer/filing/0001193125-26-101126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/0001193125-26-101126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/d94203d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:50:44.082262+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d6d9cd3d3134c1712117288e898b8579e23b09f4","claim":"Verrica Pharmaceuticals Inc. reported Fourth Quarter and Full Year 2025 results: revenue $35.6 million.","evidence_excerpt":"Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results – YCANTH ® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/0001193125-26-101126-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter and Full Year 2025"},{"label":"Revenue","value":"$35.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}